H.C. Wainwright initiated coverage on Aligos Therapeutics with a new price target
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00